Noninvasive monitoring of pharmacodynamics and kinetics of a death receptor 5 antibody and its enhanced apoptosis induction in sequential application with doxorubicin

Neoplasia (United States)

Volumn 15, Issue 8, 2013, Pages 863-874

  Weber, Thomas G ^a   Pöschinger, Thomas ^a   Galbán, Stefanie ^b   Rehemtulla, Alnawaz ^b   Scheuer, Werner ^a  

^a ROCHE DIAGNOSTICS GMBH   (Germany)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI DR5; ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 7; CISPLATIN; DEATH RECEPTOR 5; DOXORUBICIN; FLUOROURACIL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTOPSY; BIOLUMINESCENCE; CELL PERMEABILIZATION; CELL VIABILITY; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; FLUORESCENCE MICROSCOPY; GEL PERMEATION CHROMATOGRAPHY; GLIOBLASTOMA; HISTOLOGY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

EID: 84881042395     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.13932     Document Type: Article

References (44)

1. Hanahan D and Weinberg RA (2000). The hallmarks of cancer. Cell 100, 57-70.
2. Fulda S and Debatin KM (2006). Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 25, 4798-4811.
3. Roos WP and Kaina B (2006). DNA damage-induced cell death by apoptosis. Trends Mol Med 12, 440-450.
4. Almasan A and Ashkenazi A (2003). Apo2L/TRAIL: Apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev 14, 337-348.
5. Yin XM (2000). Signal transduction mediated by Bid, a pro-death Bcl-2 family proteins, connects the death receptor and mitochondria apoptosis pathways. Cell Res 10, 161-167.
6. Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T, and Reed JC (1998). IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 58, 5315-5320.
7. Kruyt FA (2008). TRAIL and cancer therapy. Cancer Lett 263, 14-25.
8. Bellail AC, Qi L, Mulligan P, Chhabra V, and Hao C (2009). TRAIL agonists on clinical trials for cancer therapy: the promises and the challenges. Rev Recent Clin Trials 4, 34-41.
9. Adams C, Totpal K, Lawrence D, Marsters S, Pitti R, Yee S, Ross S, Deforge L, Koeppen H., Sagolla M, et al. (2008). Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5. Cell Death Differ 15, 751-761.
10. Ashkenazi A (2008). Targeting the extrinsic apoptosis pathway in cancer. Cytokine Growth Factor Rev 19, 325-331.
11. Singh TR, Shankar S, Chen X, Asim M, and Srivastava RK (2003). Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo. Cancer Res 63, 5390-5400.
12. Fiveash JB, Gillespie GY, Oliver PG, Zhou T, Belenky ML, and Buchsbaum DJ (2008). Enhancement of glioma radiotherapy and chemotherapy response with targeted antibody therapy against death receptor 5. Int J Radiat Oncol Biol Phys 75, 507-516.
13. Lee MJ, Ye AS, Gardino AK, Heijink AM, Sorger PK, MacBeath G, and Yaffe MB (2012). Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. Cell 149, 780-794.
14. Coppola JM, Ross BD, and Rehemtulla A (2008). Noninvasive imaging of apoptosis and its application in cancer therapeutics. Clin Cancer Res 14, 2492-2501.
15. Galbán S, Jeon YH, Bowman BM, Stevenson J, Sebolt KA, Sharkey LM, Lafferty M., Hoff BA, Butler BL, Wigdal SS, et al. (2013). Imaging proteolytic activity in live cells and animal models. PloS One 8, e66248.
16. Poeschinger T, Renner A, Weber T, and Scheuer W (2013). Bioluminescence imaging correlates with tumor serum marker, organ weights, histology, and human DNA levels during treatment of orthotopic tumor xenografts with antibodies. Mol Imaging Biol 15, 28-39.
17. Galbán S, Jeon YH, Sharkey LM, Hoff BA, Galban CJ, Ross BD, and Rehemtulla A (2012). A genetically engineered mouse for imaging of apoptosis in a tissue specific manner. In Proceedings of the 103rd AACR Annual Meeting.
18. Johnson DR and O'Neill BP (2012). Glioblastoma survival in the United States before and during the temozolomide era. J Neurooncol 107, 359-364.
19. Adams C (2006). DR5 antibodies and uses thereof. WIPO Patent No. 2006083971.
20. Seiden MV, Ng SW, Supko JG, Ryan DP, Clark JW, Lynch T, Huang KC, Kwiatkowski D., Skarin A, and Eder JP Jr (2002). A Phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumors. Clin Cancer Res 8, 691-697.
21. Wang S, Ren W, Liu J, Lahat G, Torres K, Lopez G, Lazar AJ, Jayes-Jordan A, Liu K., Bankson J, et al. (2010). TRAIL and doxorubicin combination induces proapoptotic and antiangiogenic effects in soft tissue sarcoma in vivo. Clin Cancer Res 16, 2591-2604.
22. Guo L, Fan L, Pang Z, Ren J, Ren Y, Li J, Chen J, Wen Z, and Jiang X (2011). TRAIL and doxorubicin combination enhances anti-glioblastoma effect based on passive tumor targeting of liposomes. J Control Release 154, 93-102.
23. Zhang XD, Franco AV, Nguyen T, Gray CP, and Hersey P (2000). Differential localization and regulation of Death and Decoy Receptors for TNF-related apoptosis-inducing ligand (TRAIL) in human melanoma cells. J Immunol 164, 3961-3970.
24. Jeffrey IW, Bushell M, Tilleray VJ, Morley S, and Clemens MJ (2002). Inhibition of protein synthesis in apoptosis: differential requirements by the tumor necrosis factor α family and a DNA-damaging agent for caspases and the double-stranded RNA-dependent protein kinase. Cancer Res 62, 2272-2280.
25. Labrinidis A, Diamond P, Martin S, Hay S, Liapis V, Zinonos I, Sims NA, Atkins G. J, Vincent C, Ponomarev V, et al. (2009). Apo2L/TRAIL inhibits tumor growth and bone destruction in a murine model of multiple myeloma. Clin Cancer Res 15, 1998-2009.
26. Holoch PA and Griffith TS (2009). TNF-related apoptosis-inducing ligand (TRAIL): A new path to anti-cancer therapies. Eur J Pharmacol 625, 63-72.
27. Wiezorek J, Holland P, and Graves J (2010). Death Receptor agonists as a targeted therapy for cancer. Clin Cancer Res 16, 1701-1708.
28. Bagci-Onder T, Agarwal A, Flusberg D, Wanningen S, Sorger P, and Shah K (2012). Real-time imaging of the dynamics of death receptors and therapeutics that overcome TRAIL resistance in tumors. Oncogene 32, 2818-2827.
29. Lima C, Bayraktar S, Flores AM, MacIntyre J, Montero A, Baranda J, Wallmark J, Portera C., Raja R, Stern H, et al. (2012). Phase Ib study of drozitumab combined with first-line mFOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer. Cancer Invest 30, 727-731.
30. Zhang L and Fang B (2005). Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 12, 228-237.
31. Vitovski S, Chantry AD, Lawson MA, and Croucher PI (2012). Targeting tumourinitiating cells with TRAIL based combination therapy ensures complete and lasting eradication of multiple myeloma tumours in vivo. PLoS One 7, e35830.
32. Shankar S, Chen X, and Srivastava RK (2005). Effects of sequential treatments with chemotherapeutic drugs followed by TRAIL on prostate cancer in vitro and in vivo. Prostate 62, 165-186.
33. Keane MM, Ettenberg SA, Nau MM, Russell EK, and Lipkowitz S (1999). Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res 59, 734-741.
34. Ding L, Yuan C, Wei F, Wang G, Zhang J, Bellail AC, Zhang Z, Olson JJ, and Hao C (2011). Cisplatin restores TRAIL apoptotic pathway in glioblastomaderived stem cells through up-regulation of DR5 and down-regulation of c-FLIP. Cancer Invest 29, 511-520.
35. Hetschko H, Voss V, Seifert V, Prehn JH, and Kögel D (2008). Upregulation of DR5 by proteasome inhibitors potently sensitizes glioma cells to TRAILinduced apoptosis. FEBS J 275, 1925-1936.
36. Stolfi C, Pallone F, and Monteleone G (2012). Molecular targets of TRAILsensitizing agents in colorectal cancer. Int J Mol Sci 13, 7886-7901.
37. Qin LF and Ng IO (2002). Induction of apoptosis by Cisplatin and its effect on cell cycle-related proteins and cell cycle changes in hepatoma cells. Cancer Lett 175, 27-38.
38. Sheikh MS, Burns TF, Huang Y, Wu GS, Amundson S, Brooks KS, Fornace AJ, and el-Deiry WS Jr (1998). P53-dependent and-independent regulation of the Death Receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor α. Cancer Res 58, 1953-1958.
39. Chawla-Sarkar M, Bae SI, Reu FJ, Jacobs BS, Lindner DJ, and Borden EC (2004). Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ 11, 915-923.
40. Kim EH, Kim SU, Shin DY, and Choi KS (2004). Roscovitine sensitizes glioma cells to TRAIL-mediated apoptosis by downregulation of survivin and XIAP. Oncogene 23, 446-456.
41. Chandra D, Liu JW, and Tang DG (2002). Early mitochondrial activation and cytochrome c up-regulation during apoptosis. J Biol Chem 277, 50842-50854.
42. Condorelli F, Salomoni P, Cotteret S, Cesi V, Srinivasula SM, Alnemri ES, and Calabretta B (2001). Caspase cleavage enhances the apoptosis-inducing effects of Bad. Mol Cell Biol 21, 3025-3036.
43. He Q, Lee DI, Rong R, Yu M, Luo X, Klein M, El-Deiry WS, Huang Y, Hussain A., and Sheikh MS (2002). Endoplasmic reticulum calcium pool depletion-induced apoptosis is coupled with activation of the death receptor 5 pathway. Oncogene 21, 2623-2633.
44. Delhalle S, Duvoix A, SchnekenburgerM, Morceau F, Dicato M, and DiederichM (2003). An introduction to the molecular mechanisms of apoptosis. Ann N Y Acad Sci 1010, 1-8.